Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BeCoMe-9: A Phase 1/2 Dose Escalation and Expansion Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

NCT06611436 is registered in ClinicalTrials.gov with Be Biopharma as lead sponsor.

NCT NCT06611436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06611436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BeCoMe-9: A Phase 1/2 Dose Escalation and Expansion Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
Lead sponsor
Be Biopharma
Phase
Phase 1/2
Overall status
Terminated
Start date
December 4, 2024
Completion date
May 29, 2026
Enrollment
5 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b, hemophilia b, moderately severe or severe